Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy.
P J de KamS ZielenJonathan A BernsteinUwe BergerMarkus BergerM CuevasD CypcarA Fuhr-HorstW A GreisnerM JandlS LaßmannMargitta WormJonathan MatzE SherC SmithG C StevenRalph MosgesMohamed H ShamjiL DuBuskeF BorgheseK OluwayiT ZwingersM SeyboldO ArmfieldMatthew D HeathS J HewingsMatthias F KramerM A SkinnerPublished in: Allergy (2023)
This trial demonstrated a clinically relevant and statistically significant efficacy response to PQ Grass. Unprecedented effect sizes were reached for grass allergy of up to ≈40% compared to placebo for CSMS after only six PQ Grass injections. Both PQ Grass regimens were considered equally safe and well-tolerated. Based on enhanced efficacy profile extended regime will be progressed to the pivotal Phase III trial.